This company listing is no longer active
이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!
Aceragen 관리
관리 기준 확인 3/4
Aceragen's CEO is John Taylor, appointed in Sep 2022, he has a tenure of less than a year. His total yearly compensation is $444.06K , comprised of 17.5% salary and 82.5% bonuses, including company stock and options. He directly owns 17.45% of the company’s shares, worth $558.40K. The average tenure of the management team and the board of directors is 4.1 years and 4.3 years respectively.
주요 정보
John Taylor
최고 경영자
US$444.1k
총 보상
| CEO 급여 비율 | 17.5% |
| CEO 임기 | less than a year |
| CEO 소유권 | 17.5% |
| 경영진 평균 재임 기간 | 4.1yrs |
| 이사회 평균 재임 기간 | 4.3yrs |
최근 관리 업데이트
Recent updates
Idera Pharmaceuticals completes acquisition of Aceragen
Sep 28We're Keeping An Eye On Idera Pharmaceuticals' (NASDAQ:IDRA) Cash Burn Rate
Aug 24
We Think Idera Pharmaceuticals (NASDAQ:IDRA) Needs To Drive Business Growth Carefully
May 11Is Idera Pharmaceuticals (NASDAQ:IDRA) In A Good Position To Deliver On Growth Plans?
Mar 07When Will Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) Become Profitable?
Jan 31Idera outlines capital requirement to move tilsotolimod toward commercialization in advanced melanoma
Jan 13Could The Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) Ownership Structure Tell Us Something Useful?
Dec 27Don't Ignore The Fact That This Insider Just Sold Some Shares In Idera Pharmaceuticals, Inc. (NASDAQ:IDRA)
Dec 27Idera Pharmaceuticals receives $5M in additional proceeds from private placement
Dec 15We're Keeping An Eye On Idera Pharmaceuticals' (NASDAQ:IDRA) Cash Burn Rate
Nov 25Idera Pharma names new operations chief
Nov 17Idera Pharmaceuticals EPS misses by $0.37
Oct 29CEO 보상 분석
| 날짜 | 총 보상 | 급여 | 회사 수익 |
|---|---|---|---|
| Mar 31 2023 | n/a | n/a | -US$41m |
| Dec 31 2022 | US$444k | US$78k | -US$23m |
보상 대 시장: John's total compensation ($USD444.06K) is below average for companies of similar size in the US market ($USD760.57K).
보상과 수익: Insufficient data to compare John's compensation with company performance.
CEO
John Taylor (52 yo)
less than a year
테뉴어
US$444,062
보상
Mr. John C. Taylor serves as President, Chief Executive Officer and Director since September 28, 2022 at Aceragen, Inc. He was Chief Executive Officer of Spyryx Biosciences, Inc since December 2013 and ser...
리더십 팀
| 이름 | 위치 | 테뉴어 | 보상 | 소유권 |
|---|---|---|---|---|
| President | less than a year | US$444.06k | 17.45% $ 558.4k | |
| Associate Director of Human Resources | no data | 데이터 없음 | 데이터 없음 | |
| Director of Human Resources | no data | 데이터 없음 | 데이터 없음 | |
| Senior Vice President of Technical Operations | no data | 데이터 없음 | 데이터 없음 | |
| Global Head of Quality | no data | 데이터 없음 | 데이터 없음 | |
| Medical Director & Global Clinical Lead for Oncology | no data | 데이터 없음 | 데이터 없음 | |
| Advisor | 4.1yrs | US$993.93k | 데이터 없음 | |
| Adviser | no data | US$986.13k | 데이터 없음 |
4.1yrs
평균 재임 기간
62yo
평균 연령
경험이 풍부한 관리: ACGN's management team is considered experienced (4.1 years average tenure).
이사회 구성원
| 이름 | 위치 | 테뉴어 | 보상 | 소유권 |
|---|---|---|---|---|
| President | less than a year | US$444.06k | 17.45% $ 558.4k | |
| Independent Director | 4.3yrs | US$89.43k | 0.26% $ 8.4k | |
| Chair of the Board of Directors | 8.7yrs | US$1.43m | 0.10% $ 3.2k | |
| Independent Director | less than a year | US$11.88k | 데이터 없음 | |
| Independent Director | 7.6yrs | US$66.24k | 0% $ 0 | |
| Independent Director | 4.3yrs | US$60.12k | 0% $ 0 | |
| Member of Scientific Advisory Board | no data | 데이터 없음 | 데이터 없음 | |
| Member of Scientific Advisory Board | no data | 데이터 없음 | 데이터 없음 | |
| Member of Scientific Advisor Board | no data | 데이터 없음 | 14.31% $ 458.0k |
4.3yrs
평균 재임 기간
63.5yo
평균 연령
경험이 풍부한 이사회: ACGN's board of directors are considered experienced (4.3 years average tenure).